FDA Proposes Excluding Active Ingredients in Novo, Lilly Weight Loss Drugs from Bulk Compounding List
- May 01, 2026
- Written by AHLA Legal Staff
The Food and Drug Administration (FDA) proposed April 29 to exclude semaglutide, tirzepatide, and liraglutide—the active pharmaceutical ingredients in Novo Nordisk’s and Eli Lilly & Co.’s popular weight loss and diabetes medications—from the federal list that identifies drug substances outsourcing facilities can use for bulk compounding.
ARTICLE TAGS
You must be logged in to access this content.